The Virus That Couldn't Catch a Break

Some investors clearly bet that the committee's thumbs-up would tip the scales. They lost that bet spectacularly.

The Study Design Problem Nobody Could Fix

The FDA's objections weren't just about the missing control arm. They stacked up like a list of reasons your friend gives for why a relationship isn't working:

No way to isolate RP1's contribution. When you give two drugs together without testing either one alone, you can't say which one did the heavy lifting. The FDA called this out explicitly.

A messy patient population. The patients enrolled in IGNYTE varied widely in their prior treatments, disease characteristics, and treatment histories. That heterogeneity (fancy word for "everyone was different") made it nearly impossible to compare results against historical benchmarks.

Questionable response measurements. The FDA flagged concerns about how tumor responses were assessed using the standard RECIST criteria, noting that the sponsor's approach "confounds interpretation" and "limits FDA's ability to verify the reported results."

Replimune submitted additional analyses with its resubmissions. The FDA reviewed them and concluded they didn't change anything. Different review teams reached the same conclusion each time, specifically to rule out any internal bias. The answer kept coming back the same.

Wall Street Hit the Eject Button

The market reaction was brutal and immediate. BMO Capital Markets downgraded Replimune to Underperform with a $1 price target, down from $11. Analyst Evan Seigerman described the path forward as "long and financially challenging" and suggested the company may need to consider strategic alternatives, including returning capital to shareholders or finding a buyer.

JPMorgan cut the stock to Underweight from Neutral and removed its price target entirely. The bank had previously believed the "totality of RP1 data" could support approval. Not anymore.

One analyst had even called a third failure "highly unlikely" before the decision. That kind of confidence explains the crash; a lot of money was positioned for good news that never came.

What's Left in the Tank?

Replimune isn't a one-trick pony, at least on paper. The company has RP2 in Phase 2 trials (including a hepatocellular carcinoma study with Roche) and partnerships with major pharma players. But the financials paint a grim picture.

The company lost $247.3 million in fiscal year 2025 and burned through cash building a full commercial launch operation for RP1: sales teams, distribution networks, state licensing. All of that infrastructure is now an expensive monument to a product that can't be sold. Without aggressive cost cuts, the runway gets uncomfortably short for a company with no approved products and no revenue.

Meanwhile, rival Iovance Biotherapeutics is sitting pretty. Its cell therapy Amtagvi won FDA approval in 2024 for the same advanced melanoma population, and Jefferies analyst Andrew Tsai noted that Replimune's failure directly benefits Iovance by removing a competitive threat.

The Bigger Picture for Oncolytic Viruses

RP1's struggles aren't just Replimune's problem; they cast a shadow over the entire oncolytic virus field. The concept is elegant: engineer a virus to selectively infect and destroy cancer cells while stimulating the immune system. Amgen's T-VEC (Imlygic), approved way back in 2015, remains the only FDA-approved oncolytic virus for melanoma. Despite over 400 clinical trials conducted across the field, no one else has managed to cross the regulatory finish line in the U.S.

The technology keeps running into the same wall. Oncolytic viruses often show tantalizing early signals in small, uncontrolled studies, but proving that signal holds up under the rigorous scrutiny of a well-controlled trial has been the persistent challenge. The FDA has shown with lifileucel (Amtagvi) that it will approve therapies based on single-arm data when the response signal is overwhelmingly clear. With RP1, the signal just wasn't convincing enough.

What Happens Next

Replimune has an ongoing Phase 3 trial called IGNYTE-3 that could theoretically provide the controlled data the FDA wants. But running a large randomized trial takes years and costs a fortune, and the company's stock is now trading at levels that make fundraising painfully dilutive.

BMO's Seigerman floated the possibility of a sale or partnership with a larger company. That might be the most realistic path forward: find a deep-pocketed partner willing to fund the expensive, years-long journey the FDA has essentially mandated.

For now, Replimune serves as a cautionary tale about a fundamental tension in biotech. Companies want to move fast and file early. The FDA wants robust evidence. When those two impulses collide, especially after five years of the agency saying the same thing, investors are the ones who end up paying the price.